Investigational Drugs Oncology

Oncology Jobs

Find an open position today!

AEterna's share to rise by 32%

Following AEterna's annoucement of 2nd stage Phase II enrolment for endometrial cancer, the compagny's share closed with a 32% increase. by Caroline A. Falciola, PhD , 04/11/2008

A.P. Pharma treatment did not achieve endpoint of superiority

Although APF-530 hit the main endpoint of being comparable to Aloxi, it failed to meet the goal of superiority for the highly emetogenic delayed onset assessment. by Pierre-Philippe Luyet, PhD , 01/10/2008

News from ESMO 2008

Highlight of news related to ovarian cancer and soft tissue sarcoma presented at the ESMO meeting.17/09/2008

New US patent awarded for Lenocta

VioQuest gets a patent issued by the FDA for Lenocta, and continues trials for solid tumour cancers.29/08/2008

Bioniche Life Sciences in pivotal clinical trial for human bladder cancer

Bioniche Life Sciences Inc. is successfully undergoing its first pivotal phase III clinical trial with Urocidin for human bladder cancer.20/08/2008

Another Blow To GPC Biotech AG

GPC Biotech AG withdrew its Marketing Authorization Application for Satraplatin in Europe.11/08/2008

Progen terminates trial in Phase III

Progen's shares plunged as the company announced their decision to bring to an end the phase III trials for PI-88 drug.25/07/2008




OncologyPressreleases

SelectedOncology drugs.
PLX-4032 (?)PLX-4032 is an anticancer agent that selectively inhibits the cancer-causing BRAFV600E gene found in subsets of different cancers, including 70% of malignant melanomas and a significant number of colorectal and thyroid tumors.
DACETUZUMAB (?)SGN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, rena
RX-21202 (?)RX-21202 is a HPMA-gemcitabine being developed as an anticancer. It can overcome the downside of cytotoxic compounds, such as poor solubility, stability, and severe adverse reactions. Conjugating water-soluble and non-toxic HPMA to conventional anticancer compounds bolster efficacy while lowering to